Kiniksa Pharmaceuticals International, PLC expected to post earnings of 37 cents a share - Earnings Preview

Kiniksa Pharmaceuticals International

Today 13:40

Kiniksa Pharmaceuticals International, PLC KNSA.OQ KNSA.O is expected to  show a rise in quarterly revenue when it reports  results on October 27 for the period ending September 30 2026
The London England-based  company is expected to report a 43.9% increase in revenue to $260.161 million from $180.86 million a year ago, according to the mean estimate from 8 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Kiniksa Pharmaceuticals International, PLC is for earnings of 37 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Kiniksa Pharmaceuticals International, PLC is $98.00, about 21.3% above its last closing price of $80.79
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Jun. 30 2026
0.30
0.30
0.30
Met
0.4
Mar. 31 2026
0.21
0.20
0.27
Beat
34.2
Dec. 31 2025
0.35
0.37
0.17
Missed
-54.6​
Sep. 30 2025
0.32
0.32
0.23
Missed
-28.9
​​Jun. 30 2025
0.17
0.18
0.23
Beat
26.3
Mar. 31 2025
-0.01
0.04
0.11
Beat
161.9​
Dec. 31 2024
-0.10
0.00
-0.12
Missed
-5,900
Sep. 30 2024
-0.02
0.03
-0.18
Missed
-662.5
This summary was machine generated October 23 at 12:40 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)